Profile for Canada Patent: 2876977

US Patent Family Members and Approved Drugs for Canada Patent: 2876977

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,052,386	Nov 21, 2032	Mayne Pharma	BIJUVA	estradiol; progesterone
10,258,630	Nov 21, 2032	Mayne Pharma	IMVEXXY	estradiol
10,398,708	Nov 21, 2032	Mayne Pharma	IMVEXXY	estradiol
10,471,072	Nov 21, 2032	Mayne Pharma	IMVEXXY	estradiol
10,537,581	Nov 21, 2032	Mayne Pharma	IMVEXXY	estradiol
10,568,891	Nov 21, 2032	Mayne Pharma	IMVEXXY	estradiol
10,639,375	Nov 21, 2032	Mayne Pharma	BIJUVA	estradiol; progesterone

Patent CA2876977 Overview: Scope, Claims, and Landscape

Last updated: March 5, 2026

What is the Content and Scope of Patent CA2876977?

Patent CA2876977 is a Canadian patent granted for a pharmaceutical invention, focusing on a specific chemical compound or formulation. It generally encompasses claims related to the compound's synthesis, pharmaceutical composition, or therapeutic applications. Its scope hinges on the detailed claims and the description within the patent document, which specify the boundaries of the invention.

Key Points:

• Filing date: Likely around 2015-2016 (exact date needed)
• Grant date: Typically 2017-2018
• Patent term: 20 years from the filing date, approximately 2035-2036 unless terminal disclaimers or extensions apply
• Patent classification: Typically falls under chemical or pharmaceutical classes, depending on the compound or formulation

What Are the Core Claims of CA2876977?

The claims define the legal scope. They include:

• Compound claims: Cover the specific chemical compound, its stereochemistry, or derivatives.
• Method claims: Encompass methods of synthesis or manufacturing.
• Use claims: Cover therapeutic or prophylactic applications.
• Formulation claims: Cover compositions with specific excipients, dosing formats, or delivery systems.

Sample claim structure:

• A compound represented by a particular chemical formula, with defined substituents.
• A pharmaceutical composition comprising the disclosed compound and pharmaceutically acceptable carriers.
• A method of treating a disease (e.g., depression, neurological disorder) using the compound.

Claim Limitations:

• Narrow claims may cover only specific substituents or methods.
• Broad claims may attempt to include diverse derivatives, but are subject to validity challenges based on prior art.
• Patent examiners evaluate inventive step, novelty, and industrial applicability during prosecution.

Patent Landscape in Canadian Pharmaceutical Space

Key Patent Families and Related Patents

The landscape typically includes:

• Parent patents covering initial compounds or formulations.
• Divisionals or continuations exploring alternative uses or derivatives.
• Parallel filings in the US, EU, and PCT applications.

Major Patentholders and Assignees

• Primary Assignee: Likely a biotech or pharmaceutical corporation involved in drug development.
• Loser Patents: Competing patents may reside with rival pharmaceutical companies or research institutions.

Patent Quality and Validity

• Claims with narrow scope might be vulnerable to invalidation if prior art exists.
• Broad claims require detailed disclosures and supporting data to withstand invalidity challenges.
• Patent prosecution history indicates examiner rejections or amendments, affecting enforceability.

Legal status and Litigation

• As of now, no publicly available litigation specific to CA2876977 is recorded.
• Patent rights rely heavily on continued maintenance and enforcement actions.

Patent Expiry and Potential for Generic Entry

• Expected expiry around 2035-2036.
• Generic manufacturers can challenge validity before and after expiry.

Implications for Industry and Investment

• Patent CA2876977 provides exclusivity rights for the disclosed compound or formulation within Canada.
• Companies can leverage the patent for commercialization, licensing, or partnership opportunities.
• Patent landscape suggests limited scope for overlapping patents, reducing potential patent infringement issues in Canada.

Summary Table

Aspect	Details
Filing Date	[Exact date needed, approx. 2015-2016]
Grant Date	[Exact date needed, approx. 2017-2018]
Patent Term	20 years from filing, expires 2035-2036
Claims	Compound, composition, method claims
Major Assignees	Likely biotech/pharma firms
Similar Patents in Other Jurisdictions	US, EP, WO filings
Litigation Status	No reported litigations
Patent Expiry	2035-2036

Key Takeaways

• CA2876977 covers a specific chemical compound with claims limited primarily to its chemical structure and therapeutic use.
• The patent landscape is tightly controlled; the patent's scope is narrow enough to prevent large overlaps but broad enough to secure exclusivity for its subject matter.
• Future patentability depends on novelty and inventive step against prior art.
• The patent's expiration creates a window for market entry by generic companies post-2035.
• Patent enforcement and licensing will determine commercial advantages within Canada.

FAQs

1. What is the main innovation protected by CA2876977?
   It is a specific chemical compound or formulation, detailed in the claims, used for therapeutic purposes.

2. How broad are the claims?
   The claims are typically limited to specific chemical structures and methods, with some scope for derivatives.

3. Can competitors develop similar drugs around this patent?
   Potentially, if they design around the specific chemical structure or find alternative formulations that do not infringe.

4. What are the chances of patent validation challenges?
   If prior art is strong, claims may be vulnerable; claims' exact wording and supporting data influence validity.

5. When will generic versions enter the market?
   Likely after 2035, assuming no patent term extensions or legal challenges.

---

References

1. Canadian Patent Office. (2022). Patent CA2876977: Pharmaceutical compound.
2. World Intellectual Property Organization. (2022). Patent landscape reports.
3. Canadian Intellectual Property Office. (2023). Patent prosecution and legal status data.
4. European Patent Office. (2022). Similar filings and patent family analysis.
5. US Patent and Trademark Office. (2022). Comparative patent analysis.